ASHVATTHA THERAPEUTICS
Ashvattha Therapeutics creates products that selectively target and treat human diseases. Ashvattha enables precision targeting for therapeutics eliminating off-target toxicity, systemic side effects, and immunogenicity seen in other platforms. Ashvattha has a pipeline of nine therapeutics in neurology, oncology, and ophthalmology.
ASHVATTHA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.avttx.com
Total Employee:
11+
Status:
Active
Contact:
650-868-5853
Email Addresses:
[email protected]
Total Funding:
98 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Google Maps Global Site Tag Google Universal Analytics
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Modi Ventures
Modi Ventures investment in Series B - Ashvattha Therapeutics
Plum Alley
Plum Alley investment in Series B - Ashvattha Therapeutics
Tribe Capital
Tribe Capital investment in Series B - Ashvattha Therapeutics
Huadong Medicine
Huadong Medicine investment in Series B - Ashvattha Therapeutics
Natural Capital Investment Fund
Natural Capital Investment Fund investment in Series B - Ashvattha Therapeutics
Helios Capital
Helios Capital investment in Convertible Note - Ashvattha Therapeutics
Sakya Duvvuru
Sakya Duvvuru investment in Convertible Note - Ashvattha Therapeutics
Kingsley Advani
Kingsley Advani investment in Convertible Note - Ashvattha Therapeutics
Sand Hill Angels
Sand Hill Angels investment in Convertible Note - Ashvattha Therapeutics
Natural Capital
Natural Capital investment in Convertible Note - Ashvattha Therapeutics
Key Employee Changes
Official Site Inspections
http://www.avttx.com Semrush global rank: 7.86 M Semrush visits lastest month: 685
- Host name: ashvattha.tempurl.host
- IP address: 45.32.137.155
- Location: San Jose United States
- Latitude: 37.3387
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95113
More informations about "Ashvattha Therapeutics"
About Us โ Ashvattha Therapeutics - avttx.com
Co-founder, Board Observer, Co-Director, Center for Nanomedicine, Professor of Ophthalmology at Johns Hopkins UniversitySee details»
Ashvattha Therapeutics - Crunchbase Company Profile โฆ
Ashvattha Therapeutics is a clinical-stage biopharmaceutical company that develops precision nanomedicines for ophthalmology diseases.See details»
Overview, News & Similar companies - ZoomInfo.com
Apr 18, 2023 View Ashvattha Therapeutics (www.avttx.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees โฆSee details»
Ashvattha Therapeutics - Craft
Ashvattha Therapeutics has 5 employees across 2 locations and $19 m in total funding,. See insights on Ashvattha Therapeutics including office locations, competitors, revenue, financials, โฆSee details»
Ashvattha Therapeutics Inc (Ashvattha Therapeutics Inc) - ่ฏ็ฉ็ฎก โฆ
May 7, 2025 Ashvattha Therapeutics was founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland and incubated by Natural Capital. For more information, visit: โฆSee details»
Ashvattha Therapeutics Venture Capital and Private Equity โฆ
Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, โฆSee details»
Ashvattha Therapeutics โ Developing a New Class of Intracellular ...
Jun 10, 2025 Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of โฆSee details»
Ashvattha Therapeutics (USA) Funding: $98M
Jun 6, 2025 Ashvattha Therapeutics develops therapy thar selectively targets hyper-inflammatory macrophages responsible for excessive cytokine production in severe COVID-19...See details»
Ashvattha Presents Positive Phase 2 Data for Subcutaneous ...
Feb 10, 2025 Ashvattha Therapeutics was founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland and incubated by Natural Capital. For more information, visit: โฆSee details»
Ashvattha Therapeutics - VentureRadar
"Ashvattha Therapeutics holds the exclusive rights to a novel hydroxyl dendrimer technology developed at Johns Hopkins University enabling a new class of targeted therapies previously โฆSee details»
Ashvattha Therapeutics Announces Attendance at Upcoming โฆ
Feb 18, 2021 The webcasts will be accessible in the News section of the Ashvattha Therapeutics website at https://avttx.com. About Ashvattha TherapeuticsSee details»
Contact โ Ashvattha Therapeutics - avttx.com
Ashvattha Therapeutics (HQ) 1235 Radio Road, Suite 200 Redwood City, CA 94065See details»
News โ Ashvattha Therapeutics - avttx.com
Feb 10, 2025 Company to showcase breakthrough imaging agents advancing precision medicine in neurology and oncology REDWOOD CITY, Calif., June 17, 2025 โ Ashvattha โฆSee details»
Ashvattha Therapeutics Announces Key Executive Appointments in โฆ
Mar 1, 2022 - Company appoints Bella Oguno as Vice President, Clinical Operations, and Steve Carlos as Vice President, Manufacturing. - Their decades of experience bring proven โฆSee details»
Ashvattha Therapeutics Company Profile: , Investments, Contact ...
Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. https://avttx.comSee details»
Ashvattha Therapeutics to Present Positive Phase 2 Results for ...
May 8, 2025 Ashvattha Therapeutics was founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland and incubated by Natural Capital. For more information, visit: โฆSee details»
Ashvattha Therapeutics to Present at Upcoming Investor โฆ
Feb 2, 2023 Ashvattha Therapeutics to Present at Upcoming Investor Conferences REDWOOD CITY, Calif ., February 2, 2023 โ Ashvattha Therapeutics (โAshvatthaโ), a clinical-stage โฆSee details»
Ashvattha Therapeutics Announces Positive Interim Data from โฆ
Jun 15, 2021 Ashvattha Therapeutics Announces Positive Interim Data from Ongoing Phase 2 PRANA Clinical Study of OP-101 in Severe COVID-19 PatientsSee details»
Ashvattha Therapeutics Reports the Ability to Tune โฆ
6 days ago Novel nanomedicine radiotracer crosses blood brain barrier in patients with neuroinflammation Tumor macrophage radiotracer achieves 41.6% peak tumor uptake in โฆSee details»
Migaldendranib (MGB) โ Ashvattha Therapeutics - avttx.com
Over 10M eye injections per year = Heavy treatment burden on patients and doctors Approved and prospective drugs require a retinal ophthalmologist, a caregiver to drive to/from visits, and โฆSee details»